BIO Ventures for Global Health has created a library of reports that encompass our extensive research on global health issues, the biopharmaceutical industry, and research and development (R&D) for new medicines. These publications:

• Describe the challenges faced by patients in the developing world
• Illustrate how biotechnology companies are uniquely suited to address those challenges
• Explore the incentives needed to encourage the biotechnology industry to invest in R&D for new medicines for the infectious diseases of poverty

Reports

• Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape
  Analyzes which product developers are doing what in the creation of new drugs and vaccines that tackle 23 neglected diseases.
• The Global Health Primer  
  Provides an introduction to neglected tropical diseases and how the technology biotech companies are already developing can be used to solve unmet medical needs in poor countries. 
• The Vaccine Landscape for Neglected Diseases: A Perspective from the Global Health Primer
  Offers an overview of trends in vaccine development for neglected diseases.
• The Diagnostics Innovation Map: Medical Diagnostics for the Unmet Needs of the Developing World
  Outlines the groundbreaking technologies that are paving the way for rapid, accurate diagnoses in the developing world.
• The Case for Investment in Enterotoxigenic Escherichia coli Vaccines                                                                                                                                                                   Provides relevant information for product developers interested in the development of ETEC vaccines.
• Closing the Global Health Innovation Gap: A Role for the Biotechnology Industry in Drug Discovery for Neglected Diseases
  Highlights the biotechnology companies that have the scope, scale, and proven track records to develop new drugs for neglected diseases.

• Tuberculosis Vaccines: The Case for Investment  
  Illustrates how a new tuberculosis vaccine could have a potential global market of $1 billion.
• Advance Market Commitments to Stimulate Industry Investment in Global Health Product Development: A Report on the Biotech Industry’s Perspective
  Reveals how Advance Market Commitments (AMCs) can serve as incentives that attract biotechnology companies to develop new vaccines for neglected diseases.